Monday, 25 November 2013

Latest Report-Cardiovascular Diseases Therapeutics Market In Asia-Pacific To 2019 - Promising Pipeline Drugs To Offset Revenue Decline From Generic Erosion And Off-Label Use

Pharmaceutical research, "Cardiovascular Diseases Therapeutics Market in Asia-Pacific to 2019 - Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use", which provides insights into three cardiovascular therapeutic indications in in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

To know the complete report:-


Disease overview and treatment usage patterns
Market size and forecast for heart failure, MI and ACS in APAC market from 2012 to 2019
Major marketed products for the indications types covered
In-depth pipeline analysis for heart failure, MI and ACS
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements in the cardiovascular market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the cardiovascular market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Click Here To Download Sample Report:- 

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction

3 Therapeutic Landscape
3.1 Heart Failure
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Co-morbidities and Complications
3.1.5 Diagnosis
3.1.6 Classification
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Myocardial Infarction
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Co-morbidities and Complications
3.2.5 Diagnosis
3.2.6 Classification
3.2.7 Treatment Options
3.3 Acute Coronary Syndrome
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Treatment Options
4 Marketed Products
4.1 Heart Failure
4.2 Myocardial Infarction
4.3 Acute Coronary Syndrome
4.4 Key Marketed Products
4.4.1 Arixtra (GlaxoSmithKline plc)
4.4.2 Brilinta (AstraZeneca plc)
4.4.3 Crestor (AstraZeneca plc)
4.4.4 Diovan (valsartan) and Diovan HCT/Co-Diovan (valsartan and hydrochlorothiazide)
4.4.5 Atacand (candesartan)
4.4.6 Lipitor (Atorvastatin Tablets)
4.4.7 Clopidogrel bisulfate
4.4.8 Angiomax (bivaluridin)
4.4.9 Lovenox (enoxaparin sodium injection)
4.4.10 Norvasc (amlodipine)
4.4.11 Coreg
4.4.12 Ivabradine (Les Laboratoires Servier SAS)
4.4.13 Toprol-XL

M/s  Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948

No comments:

Post a Comment